Experienced executives fill senior roles in
business development, M&A, clinic operations and design, and
corporate communications
VANCOUVER, BC, May 13, 2021 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSXV: NUMI), a mental health care
company advancing innovative treatments and safe, evidence-based
psychedelic-assisted therapies, today announced the appointments of
five experienced leaders to support strategic growth initiatives
across the Company's three divisions – Numinus Health, Numinus
R&D and Numinus Bioscience.
The new hires fill key roles in innovation, communications,
business development, mergers and acquisitions, market research and
clinic operations. They will support the Company's goals to expand
its clinic network internationally, develop and deliver safe and
effective psychedelic-assisted psychotherapies, and enhance
laboratory capabilities.
"At Numinus, our rapidly growing team of proven and experienced
medical, business and clinical leaders are building the future of
mental health care," said Payton
Nyquvest, President, CEO and Chair at Numinus. "Today's new
hires are collaborative leaders who have the expertise and ambition
to effectively scale our Company while supporting our vision to
help people to heal and be well."
The Numinus team additions include:
- Wajahat Ali, Director of
Mergers and Acquisitions, is an expert in data-driven corporate
finance with extensive experience in private equity, valuations,
financial modeling, planning, analysis and restructuring. As
director of corporate development, he spearheaded Lifemark
Health Group's acquisition strategies and managed the transaction
process from offer to integration.
- Jason Lapensee, Vice President of National Clinic
Operations, is an accomplished leader in the healthcare
industry. Most recently serving as Director of Operations at Dawson
Dental Centres, he played a key role in developing the operational
framework to scale the business from 12 to 35 practices over seven
years.
- Ian Noble, Chief
Communications Officer, is a communications and media executive
with deep experience in capital markets, issues management, brand,
and integrated awareness and advocacy campaigns. He recently served
as VP, Media and Financial Communications, Edelman Vancouver.
- Raseel Sehmi, Vice President of Business Development &
Strategic Partnerships, offers more than 15 years of
international and cross-sector leadership experience, most recently
as Director, Global Partnerships & Business Development with
ATB Ventures. She has a track record of enabling digital innovation
across Canada, and helping
pioneering companies accelerate business growth, innovation and
social impact.
- Pam Sethi, Vice President of
Experience Design & Innovation, is an award-winning leader
in mental health innovation. She has extensive healthcare and
innovation design experience in the public and private sectors,
nationally and globally, and most recently served as Chief
Innovation Officer at the Institute for Advancement in Mental
Health.
Over the past few months, Numinus has also added employees in
sales, marketing, people and culture, market research and clinic
operations, and promoted clinical leadership from within. The
Company continues to grow and add staff, and currently has more
than 25 open positions.
Numinus engages market maker
Numinus has retained the services of Generation IACP Inc.
("GIACP") to provide market-making services to the Company. GIACP
has agreed to comply with all applicable securities laws and the
policies of the TSX Venture Exchange in providing such services to
the Company. GIACP will receive a monthly fee of CDN$7,500 plus applicable taxes. The agreement
between the Company and GIACP dated April
26, 2021 (the "Agreement") is for an initial term of six
months and shall be automatically renewed for subsequent six month
periods (collectively, the "Term") unless the Company provides
written notice of termination to GIACP at least 30 days prior to
the end of the Term or GIACP provides a written notice of
termination to the Company. Commencing on the first anniversary of
the Agreement, the fee payable to GIACP will automatically increase
annually by 3.0%. No stock options or other compensation are being
granted in connection with the engagement.
GIACP is arm's length to the Company. GIACP's market making
activity will be primarily to correct temporary imbalances in the
supply and demand of the common shares in the capital of the
Company (the "Shares"). GIACP will be responsible for the costs it
incurs in buying and selling the Shares, and no third party will be
providing funds or securities for market making
activities.
About Numinus
Numinus Wellness (TSX-V: NUMI) empowers
people to heal and be well through the development and delivery of
innovative mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus Wellness model -
including psychedelic production, research and clinic care
- is at the forefront of a transformation aimed at healing
rather than managing symptoms for depression, anxiety, trauma, pain
and substance abuse. At Numinus, we are leading the integration of
psychedelic-assisted therapies into mainstream clinical practice,
and building the foundation for a healthier society.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
and Instagram.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of applicable
securities laws. All statements that are not historical facts,
including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements". Forward-looking statements can be
identified by the use of words such as "plans", "expects" or "does
not expect", "is expected", "estimates", "intends", "anticipates"
or "does not anticipate", or "believes", or variations of such
words and phrases or statements that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, among others, dependence on obtaining and
maintaining regulatory approvals, including acquiring and renewing
federal, provincial, municipal, local or other licences and any
inability to obtain all necessary governmental approvals, licences
and permits to operate and expand the Company's facilities;
regulatory or political change such as changes in applicable laws
and regulations, including federal and provincial legalization of
psychedelic therapies, due to inconsistent public opinion,
perception of the medical-use of psychedelics, delays or
inefficiencies or any other reasons; any other factors or
developments which may hinder market growth; the Company's limited
operating history and lack of historical profits; reliance on
management; the Company's requirements for additional financing,
and the effect of capital market conditions and other factors on
capital availability; competition, including from more established
or better financed competitors; the need to secure and maintain
corporate alliances and partnerships, including with research and
development institutions, customers and suppliers; the development
and implementation of medical protocols and treatment standard
operating procedures for the use of psychedelic therapies; the
Company's goals to develop and implement partnerships with research
organizations and other key players in the integrative mental
health industry; the Company's ability to successfully withstand
the economic impact of COVID-19; the medical benefits, safety,
efficacy, dosing and social acceptance of psychedelics; the
approval and/or success of compassionate access clinical trials;
the cultivation and harvest of Psilocybe mushrooms; and the
availability of trained personnel and medical professionals. These
factors should be considered carefully, and readers are cautioned
not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other risk factors that cause actions,
events or results to differ from those anticipated, estimated or
intended. There can be no assurance that forward-looking statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in forward-looking
statements. The Company has no obligation to update any
forward-looking statement, even if new information becomes
available as a result of future events, new information or for any
other reason except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Numinus Wellness Inc.